### SPECIAL FEATURES

#### CCR Pediatric Oncology Series
Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop: clinccancerres.aacrjournals.org/pediatricseries

**e133** The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass
David Malkin, Kim E. Nichols, Joshua D. Schiffman, Sharon E. Plon, and Garrett M. Brodeur

### Highlights of This Issue 6379

#### CCR Translations

**6381** Sarcomatoid Renal Cell Carcinoma: The Apple Doesn’t Fall Far from the Tree
Paulo Bergerot, Neeraj Agarwal, Sumanta K. Pal, and Jeremy Jones
See related article, p. 6686

#### CCR Drug Updates

**6384** FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen
Christy L. Osgood, Meredith K. Chuk, Marc R. Theoret, Lan Huang, Kun He, Leah Her, Patricia Keegan, and Richard Pazdur

#### Molecular Pathways

**6390** Molecular Pathways: Targeting the Microenvironment of Liver Metastases
Simon Milette, Jason K. Sicklick, Andrew M. Lowy, and Pnina Brodt

### CANCER THERAPY: CLINICAL

**6400** Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Malika S. Dhawan, Imke H. Bartelink, Rahul Raj Aggarwal, Jim Leng, Jenna Z. Zhang, Nela Pawlowska, Manuela Terranova-Barberio, Jennifer A. Grabowska, Andrew Gewitz, Amy J. Chien, Mark Moaser, Robin K. Kelley, Tayeba Maktabi, Scott Thomas, and Pamela N. Munster

**6411** Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean-Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, and Ahmad Awada

**6421** Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Shaibly Mehrotra, Mathangi Gopalakrishnan, Jogaarao Gobburu, Jiuping Ji, Jacqueline M. Greer, Richard Piekacz, Judith E. Karp, Keith W. Pratz, and Michelle A. Rudek

**6430** Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Charles F. Craddock, Aimee E. Houlton, Lynn Swun Quek, Paul Ferguson, Emma Ghandi, Corran Roberts, Marlen Metzner, Natalia Garcia-Martin, Alison Kennedy, Angela Hamblin, Manoj Raghavan, Sandeep Nagra, Louise Dudley, Keith Wheatley, Mary Frances McMullin, SriNivas P. Pillai, Richard J. Kelly, Shamyla Siddique, Michael Dennis, Jamie D. Cavenagh, and Paresh Vyas

**6441** A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma

**6450** Underreporting of Research Biopsies from Clinical Trials in Oncology
Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensr Jr, James Yao, Lee M. Ellis, Alda I. Tam, and Michael J. Overman
PERSONALIZED MEDICINE AND IMAGING

6458 Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Elena Martínez-García, Antoine Lesur, Laura Devis, Silvia Cabrera, Xavier Matias-Guiu, Marc Hirschfeld, Jasmín Asberger, Jan van Oostrum, María de los Ángeles Casares de Cal, Antonio Gómez-Tato, Jaume Reventos, Bruno Domon, Eva Colas, and Antonio Gil-Moreno

6468 A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Kurt W. Evans, Erkan Yuca, Argun Akcakanat, Stephen M. Scott, Natalia Paez Arango, Xiaofeng Zheng, Ken Chen, Coya Tapia, Emily Tarco, sabine S. Enfield, Ian Backstrom, Corinna Warburton, Donald Yapp, Debu Tripathy, Gordon B. Mills, and Funda Meric-Bernstam

6478 An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia
Ronishouval, Annalisa Ruggeri, Myriam Labopin, Mohamad Mohy, Guillermo Sanz, Gerard Michel, Iguilen Kuball, Patrice Chevallier, Amal Al-Seraihy, Noel-Jean Lioe, Cristina Díaz de Heredia, William Arce, Didier Blaise, Vanderson Rocha, Joshua Fein, Ron Unger, Frederic Baron, Peter Bader, Eliane Guémac, and Amon Nagler

6487 Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer

6498 89Zr-anti-γH2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
James C. Knight, Michael J. Mosley, Luisa Contreras Bravo, Veerle Kerameuskens, P. Danny Allen, Somnath Mukherjee, Eric O’Neill, and Bart Cornelissen

6505 Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER-/HER2- Breast Cancer
Bas H. M. van der Velden, Sjoerd G. Elias, Tycho Bissemeijer, Claudette E. Loos, Max A. Viergever, Lodewijk F.A. Wessels, and Kenneth G. A. Gilhuys

6516 Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer
Jin Liu, Mikael Agopiantz, Joël Poupouz, Zhenzi Wu, Pierre-Alexandre Just, Bruno Borghese, Evelyne Sigal-Bendirdjian, Guillaume Gauchotte, Anne Gompel, and Patricia Forgez

6529 Targeting RNA-Polymerase 1 in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer
Robert Cornelison, Zachary C. Dobbins, Ashwini A. Katre, Dae Hoon Jeong, Yinfeng Zhang, Dongguan Chen, Yuliya Petrova, Danielle C. Ilaneza, Adam D. Steg, Laura Parsons, David A. Schneider, and Charles N. Landen

6541 Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation

6555 In Vivo Validation of PAPSS1 (3-phosphoadenosine 5-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Ada W. Y. Leung, Chansey J. Veinotte, Nicole Melong, Min Hee Oh, Kent Chen, Katey S. S. Enfield, Ian Backstrom, Corinna Warburton, Donald Yapp, Jason N. Berman, Marcel B. Bally, and William W. Lockwood

6567 Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Puyu Shi, You-Take Oh, Liang Deng, Guojing Zhang, Guoqing Qian, Shuo Zhang, Hui Ren, Grant Wu, Benjamin Legendre, Emily Anderson, Suresh S. Ramalingam, Taofeek K. Owonikoko, Mingwei Chen, and Shi-Yong Sun
The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Shu-Xiong Zeng, Yanjun Zhu, Ai-Hong Ma, Weimin Yu, Hongyong Zhang, Tzu-Yin Lin, Wei Shi, Clifford G. Tepper, Paul T. Henderson, Susan Airhart, Jian-Ming Guo, Chuan-Liang Xu, Ralph W. deVere White, and Chong-Xian Pan

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Max Kates, Abhijit Date, Takahiro Yoshida, Umara Afzal, Pranjali Kanvinde, Taarika Babu, Nikolai A. Sopko, Hotaka Matsui, Noah M. Hahn, David J. McConkey, Alexander Baras, Justin Hanes, Laura Ensign, and Trinity J. Bivalacqua

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Elizabeta A. Rojas, Luis Antonio Corchete, Laura San-Segundo, Juan F. Martínez-Blanch, Francisco M. Codoñer, Teresa Paino, Noemi Puig, Ramón García-Sanz, María Victoria Mateos, Enrique M. Ocio, Irena Misiewicz-Krzeminska, and Norma C. Gutiérrez

131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Matthias D’Huyvetter, Jens De Vos, Catarina Xavier, Marek Pruszynski, Yann G.J. Sterckx, Sam Massa, Geert Raes, Vicky Caveliers, Michael R. Zahutsky, Tony Lahoutte, and Nick Devoogdt

The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells
Zhao Yang, Luyun He, Kaisu Lin, Yun Zhang, Aihua Deng, Yong Liang, Chong Li, and Tingyi Wen

Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Anna Kreutzman, Beatriz Colom-Fernández, Anna Marcos Jiménez, Mette Ilander, Carlos Cuesta-Mateos, Yaiza Pérez-García, Cristina Delgado Árvalo, Oscar Brück, Henna Hakonen, Jani Saarelä, Alvaro Ortega-Carrion, Ana de Rosendo, Alba Juanes-Garcia, Juan L. Stogmann, Satu Mustjoki, Miguel Vicente-Manzanares, and Cecilia Muñoz-Calleja
6708 Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, Lei Tian, Jane L. Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano C. Mantelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selena, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Lætitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis-Filho, Roger A. Greenberg, Mark E. Robson, and Nicholas C. Turner

6721 Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Laura E. Thomas, Joanna J. Hurley, Elena Meuser, Sian Jose, Kevin E. Ashelford, Matthew Mort, Shelley Idziaszczyk, Julie Maynard, Helena Leon Brito, Manon Harry, Angharad Walters, Meera Raja, Sarah-Jane Walton, Sunil Dolwani, Geraint T. Williams, Meleri Morgan, Morgan Moorghen, Susan K. Clark, and Julian R. Sampson

6733 Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance
Amber E. Bannon, Jason Kent, Isaac Forquer, Ajia Town, Lillian R. Klug, Kelly McCann, Carol Beadling, Oliver Harismendy, Jason K. Sicklick, Christopher Corless, Upwal Shinde, and Michael C. Heinrich

6744 Numb−/low Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling
Yanjing Guo, Kai Zhang, Chaping Cheng, Zhongzhong Ji, Xue Wang, Minglei Wang, Mingliang Chu, Dean G. Tang, Helen He Zhu, and Wei-Qiang Gao

ABOUT THE COVER
The cover shows a section of low-grade serous ovarian carcinoma. Inhibition of neurotensin receptor 1 in ovarian cancer is correlated with higher carboplatin response. For details, see the article by Liu and colleagues on page 6516 of this issue.